Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 11, 2013, Pages 2059-2062

  Mosnier, L O ^a   Fernandez J A ^a   Davis, T P ^b   Zlokovic, B V ^c   Griffin, J H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ALANINE; ALTEPLASE; LYSINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; ANTICOAGULANT AGENT; PLASMINOGEN; PROTEIN C; RECOMBINANT PROTEIN; THROMBIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; BRAIN ISCHEMIA; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; DRUG HALF LIFE; FIBRINOLYSIS; HUMAN; LETTER; NEUROPROTECTION; NEUROTOXICITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; WILD TYPE; BLOOD CLOTTING; DOSE RESPONSE; FIBRINOLYTIC THERAPY; GENETIC VARIABILITY; GENETICS; ISCHEMIA; METABOLISM; MUTATION; PATHOLOGY; STROKE; TIME;

ALANINE; ANTICOAGULANTS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VARIATION; HUMANS; ISCHEMIA; MUTATION; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN; PROTEIN C; RECOMBINANT PROTEINS; STROKE; THROMBIN; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84887553311     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12400     Document Type: Letter

References (14)

1. Lyden PD, Lees KR, Davis SM. Alteplase for acute stroke revisited: the first 10 years. Lancet Neurol 2006; 5: 722-4.
2. Wechsler LR, Jovin TG. Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time. Stroke 2012; 43: 2517-9.
3. Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, Griffin JH, Zlokovic BV. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001; 103: 1799-805.
4. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-42.
5. Zlokovic BV, Griffin JH. Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci 2011; 34: 198-209.
6. Liu D, Cheng T, Guo H, Fernandez JA, Griffin JH, Song X, Zlokovic BV. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004; 10: 1379-83.
7. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, Liu D, Maggirwar SB, Deane R, Fernandez JA, LaRue B, Griffin JH, Chopp M, Zlokovic BV. Activated protein C inhibits tissue plasminogen activator induced brain hemorrhage. Nat Med 2006; 12: 278-85.
8. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernandez JA, Griffin JH, Zlokovic BV. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004; 41: 563-72.
9. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-72.
10. Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activated fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007; 282: 33022-33.
11. Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernández JA, Chow N, Griffin JH, Zlokovic BV. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci 2009; 29: 1119-30.
12. Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, Zlokovic BV. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke 2012; 43: 2444-9.
13. Williams PD, Zlokovic BV, Griffin JH, Pryor KE, Davis TP. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des 2012; 18: 4215-22.
14. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Atheroscler Thromb Vasc Biol 2006; 26: 2445-53.